Celldex (CLDX) AI Stock Analysis

• Market Cap: $1.46B
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: -30.25%
• EPS Growth: -9.70%
• Country: US
• Employees: 186
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 66,406,550
• 10 Day Avg. Volume: 1,820,738
• 30 Day Avg. Volume: 1,368,104
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 126.05
• Enterprise Value/Gross Profit: 146.82
• Enterprise Value/Ebitda: -3.15
• 1Y Price Target: $52.38
• Price Target Upside: 129.94% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 50 Neutral
• Price Target: $23.50 ▲(3.16% Upside)

Celldex's overall stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. Technical analysis provides some support with a stable upward trend, while valuation remains a concern due to negative earnings. Corporate events offer a mixed outlook, with strategic initiatives partially offsetting the halted drug development.

Positive Factors

Phase 3 Development

The safety data from the trial boosts confidence in barzolvolimab's use in ongoing Phase 3 development for chronic urticarias.

Safety and Tolerability

Barzolvolimab's safety and tolerability profile was clean with no anaphylaxis, no hypersensitivity, and no treatment-related serious adverse events.

Negative Factors

Clinical Outcomes

No symptomatic or endoscopic improvements were observed with barzolvolimab at week 12 compared to placebo.

Efficacy in Eosinophilic Esophagitis

The Phase 2 trial did not meet key endpoints on symptom improvement in eosinophilic esophagitis compared to placebo.

Program Discontinuation

The company announced the discontinuation of the EoE program.

Celldex Business Overview & Revenue Model

Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

How the Company Makes Money

Celldex generates revenue through several key streams, primarily from the development and commercialization of its therapeutic products. The company may earn revenue from product sales once its therapies receive regulatory approval and are marketed. Additionally, Celldex often engages in partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments as development progresses, and royalties on sales once products are commercialized. These partnerships are critical for funding research and development efforts and expanding market reach. Grant funding and research contracts may also contribute to its earnings, although product sales and collaborations remain the primary sources of revenue.

Celldex Financial Statement Overview

Summary

Celldex shows modest revenue growth but faces substantial losses with negative net income and EBIT margins. The balance sheet is strong with a high equity ratio and minimal leverage, but cash flow is challenged with negative free cash flow, indicating reliance on external funding.

Income Statement

Celldex shows modest revenue growth with a 7.7% increase in the most recent TTM period. However, the company is struggling with substantial losses, as evidenced by negative net income and EBIT margins. The gross profit margin remains positive at 78.6%, but the net profit margin is significantly negative at -2366.6%, indicating the company is not yet profitable. The biotechnology industry often experiences prolonged periods of negative earnings due to high R&D expenses.

Balance Sheet

The balance sheet is relatively strong with a high equity ratio of 95.1%, which denotes a solid capital structure. The debt-to-equity ratio is very low at 0.005, suggesting minimal leverage. Despite these strengths, the company is facing consistent net losses, impacting its return on equity, which stands at -25.4% in the TTM period.

Cash Flow

Celldex's cash flow is challenged, with a negative free cash flow of -$171.9 million in the TTM period. The operating cash flow to net income ratio is slightly positive at 0.96, indicating some alignment with reported losses. However, the free cash flow to net income ratio is negative, reflecting operational cash burn. Positive financing cash flow suggests reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.79M	7.02M	6.88M	2.36M	4.65M	7.42M
Gross Profit	4.97M	7.02M	-111.13M	-79.90M	1.58M	-35.12M
EBITDA	-231.40M	-191.90M	-139.03M	-104.20M	-66.08M	-45.64M
Net Income	-199.61M	-157.86M	-141.43M	-112.33M	-70.51M	-59.78M
Balance Sheet
Total Assets	692.41M	792.34M	465.63M	352.74M	444.65M	235.84M
Cash, Cash Equivalents and Short-Term Investments	630.34M	725.28M	423.60M	304.95M	408.25M	194.42M
Total Debt	3.03M	3.81M	2.54M	4.03M	3.04M	3.48M
Total Liabilities	37.00M	45.34M	36.46M	26.53M	25.18M	26.48M
Stockholders Equity	655.41M	747.00M	429.17M	326.20M	419.48M	209.36M
Cash Flow
Free Cash Flow	-187.06M	-159.70M	-109.11M	-105.56M	-62.16M	-41.96M
Operating Cash Flow	-186.19M	-157.78M	-107.29M	-103.73M	-60.91M	-40.40M
Investing Cash Flow	164.60M	-290.13M	-105.78M	89.94M	-216.16M	-98.22M
Financing Cash Flow	1.89M	441.45M	218.46M	4.08M	272.37M	171.23M

Celldex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 22.78 is above the 20-day moving average (MA) of 22.71, above the 50-day MA of 22.38, and above the 200-day MA of 22.07, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 51.24 is Neutral, neither overbought nor oversold. The STOCH value of 72.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.

Celldex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	61 Neutral	$1.52B	―	-62.99%	―	5.90%	-0.36%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
CLDX	50 Neutral	$1.46B	―	-27.17%	―	-30.25%	-9.70%
TVTX	49 Neutral	$1.89B	―	-705.73%	―	87.94%	57.84%
JANX	45 Neutral	$1.37B	―	-12.82%	―	-97.10%	-96.30%
ETNB	42 Neutral	$1.36B	―	-86.86%	―	―	-82.75%
VERA	39 Underperform	$1.44B	―	-54.83%	―	―	-62.51%

Celldex Corporate Events

Celldex Halts Barzolvolimab Development for EoE

On August 19, 2025, Celldex Therapeutics announced results from its Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). The study met its primary endpoint by demonstrating significant mast cell depletion in the gastrointestinal tract. However, this did not translate into improved clinical outcomes, leading Celldex to halt further development of barzolvolimab for EoE. The company remains committed to advancing barzolvolimab in other conditions where mast cells play a crucial role, such as chronic urticaria and atopic dermatitis.

Celldex Approves Equity Plan Amendment and Elects New Director

On June 5, 2025, Celldex Therapeutics held its Annual Meeting of Stockholders, where several key decisions were made, including the approval of an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance by 2,000,000. Additionally, Denice M. Torres was elected to the Board of Directors, bringing extensive leadership experience from the pharmaceutical and consumer healthcare sectors. The election of new board members and the amendment to the equity plan are expected to bolster Celldex’s strategic growth and operational capabilities as it advances its clinical programs, particularly with the promising drug barzolvolimab.